BackgroundCheck.run
Search For

Elliott G Klein, 31659 S Cloverdale Ave APT 303, Los Angeles, CA 90036

Elliott Klein Phones & Addresses

659 S Cloverdale Ave APT 303, Los Angeles, CA 90036    323-9326349   

Seattle, WA   

17708 Alder Way, Lynnwood, WA 98037    425-7428381   

Education

School / High School: State University of New York at Buffalo

Ranks

Licence: New York - Currently registered Date: 1979

Mentions for Elliott G Klein

Career records & work history

Lawyers & Attorneys

Elliott Klein Photo 1

Elliott Warren Klein - Lawyer

Licenses:
New York - Currently registered 1979
Education:
State University of New York at Buffalo
Elliott Klein Photo 2

Elliott Klein - Lawyer

Specialties:
Workers Compensation, Employer Liability, Products Liability, General Liability Defense, Subrogation, Administrative and Public, Oil & Gas, Insurance, Labor-Employment, Environmental and Natural Resources, Litigation: Personal Injury
ISLN:
905839064
Admitted:
1979
University:
State University of New York at Buffalo, B.A., 1975
Law School:
State University of New York at Buffalo, J.D., 1978

Resumes & CV records

Resumes

Elliott Klein Photo 32

Account Executive

Location:
83 south King St, Seattle, WA 98104
Industry:
Marketing And Advertising
Work:
Team One
Account Executive
Wongdoody May 1, 2016 - Oct 2017
Account Executive at Wongdoody
Wongdoody Mar 2015 - Apr 2016
Assistant Account Executive
Wongdoody Oct 2014 - Mar 2015
Strategy and New Business Freelancer and Intern
Ey-Society Jun 2014 - Sep 2014
Associate Intern
Huskycreative Sep 2013 - Jun 2014
Account Executive
Mslgroup Jun 2013 - Sep 2013
Public Relations Intern
Intercollegiate Marketing Competition Feb 2013 - Feb 2013
Case Competition
Donate Life America Case Study Dec 2012 - Dec 2012
Case Competition
Dollar Development Apr 2012 - May 2012
Muralist
Education:
University of Washington - Michael G. Foster School of Business 2012 - 2014
Bachelors, Bachelor of Arts, Business Administration, Marketing
Cascadia College 2011 - 2012
Menlo College 2010 - 2011
Lynnwood High School
University of Washington
Skills:
Management, Time Management, Leadership, Editing, Communication, Presentations, Organization, Advertising, Indesign, Marketing Strategy, Social Media, Marketing, Merchandising, Public Relations, Public Speaking, Event Planning, Illustrator, Social Media Marketing, Strategic Planning, Marketing Communications
Languages:
English
Elliott Klein Photo 33

Associate Intern

Location:
Seattle, WA
Work:
Society Consulting
Associate Intern

Publications & IP owners

Us Patents

Synthesis And Use Of Retinoid Compounds Having Negative Hormone And/Or Anatgonist Activities

US Patent:
6469028, Oct 22, 2002
Filed:
Mar 28, 2001
Appl. No.:
09/821673
Inventors:
Elliott S. Klein - Marina del Rey CA
Alan T. Johnson - Rancho Santa Margarita CA
Andrew M. Standeven - Corona del Mar CA
Richard L. Beard - Newport Beach CA
Samuel J. Gillett - Albany CA
Tien T. Duong - Irvine CA
Sunil Nagpal - Lake Forest CA
Vidyasagar Vuligonda - Irvine CA
Min Teng - Aliso Viejo CA
Roshantha A. Chandraratna - Mission Viejo CA
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
C07D21514
US Classification:
514311, 514314, 514432, 514456, 546167, 546168, 549 23, 549362
Abstract:
Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity.

Male Anti-Fertility Agents

US Patent:
6521641, Feb 18, 2003
Filed:
Jun 9, 2000
Appl. No.:
09/591253
Inventors:
Elliott S. Klein - Marina Del Rey CA
Yang-Dar Yuan - Irvine CA
Roshantha A. Chandraratna - Laguna Hills CA
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61P 1516
US Classification:
514333, 514332, 514337, 514456, 514841, 514454, 514437, 514432, 514411, 514412, 514438, 514468
Abstract:
Methods and compositions for inhibiting or preventing spermatogenesis in a male mammal. Also disclosed are compounds and formulations for use in such methods.

Methods Of Treating Hyperlipidemia

US Patent:
2002019, Dec 19, 2002
Filed:
May 3, 2001
Appl. No.:
09/848159
Inventors:
Yang-Dar Yuan - Irvine CA, US
Scott Thacher - Costa Mesa CA, US
Elliott Klein - Danbury CT, US
Roshantha Chandraratna - Laguna Hills CA, US
Assignee:
Allergan Sales, Inc. - Irvine CA
International Classification:
A61K031/47
A61K031/353
A61K031/38
US Classification:
514/311000, 514/432000, 514/456000
Abstract:
The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.

Male Anti-Fertility Agents

US Patent:
2003014, Jul 31, 2003
Filed:
Nov 25, 2002
Appl. No.:
10/304665
Inventors:
Elliott Klein - Marina Del Rey CA, US
Yang-Dar Yuan - Irvine CA, US
Roshantha Chandraratna - Laguna Hills CA, US
Assignee:
Allergan Sales, Inc.
International Classification:
A61K031/695
A61K031/655
A61K031/506
A61K031/501
A61K031/497
A61K031/4709
A61K031/47
A61K031/4436
A61K031/427
A61K031/422
A61K031/4178
A61K031/416
A61K031/382
A61K031/353
US Classification:
514/150000, 514/311000, 514/456000, 514/432000, 514/252010, 514/252030, 514/252040, 514/255050, 514/256000, 514/365000, 514/372000, 514/397000, 514/314000, 514/063000, 514/337000, 514/406000
Abstract:
Methods and compositions for inhibiting or preventing spermatogenesis in a male mammal. Also disclosed are compounds and formulations for use in such methods.

Synthesis And Use Of Retinoid Compounds Having Negative Hormone And/Or Antagonist Activities

US Patent:
2003021, Nov 27, 2003
Filed:
May 27, 2003
Appl. No.:
10/446580
Inventors:
Elliott Klein - Marina Del Rey CA, US
Andrew Standeven - Ventura CA, US
Sunil Nagpal - Lake Forest CA, US
Roshantha Chandraratna - Mission Viejo CA, US
International Classification:
G01N033/53
A61K031/59
A61K031/455
A61K031/192
A61K031/203
A61K031/195
US Classification:
435/007100, 514/557000, 514/559000, 514/355000, 514/567000, 514/569000, 514/167000
Abstract:
Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

Methods Of Treating Hyperlipidemia

US Patent:
2005017, Aug 4, 2005
Filed:
Dec 17, 2004
Appl. No.:
11/016534
Inventors:
Yang-Dar Yuan - Irvine CA, US
Scott Thacher - Costa Mesa CA, US
Elliott Klein - Danbury CT, US
Roshantha Chandraratna - Laguna Hills CA, US
Assignee:
Allergan, Inc. - Irvine CA
International Classification:
A61K031/47
A61K031/382
A61K031/353
US Classification:
514312000, 514456000, 514432000
Abstract:
The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.

Male Anti-Fertility Agents

US Patent:
2007005, Mar 8, 2007
Filed:
Aug 14, 2006
Appl. No.:
11/503635
Inventors:
Elliott Klein - Marina Del Rey CA, US
Yang-Dar Yuan - Irvine CA, US
Roshantha Chandraratna - Laguna Hills CA, US
International Classification:
A61K 31/695
A61K 31/47
A61K 31/382
A61K 31/353
A61K 31/195
US Classification:
514063000, 514311000, 514456000, 514432000, 514563000
Abstract:
Methods and compositions for inhibiting or preventing spermatogenesis in a male mammal. Also disclosed are compounds and formulations for use in such methods.

Methods Of Treating Hyperlipidemia

US Patent:
2008021, Sep 4, 2008
Filed:
Feb 27, 2008
Appl. No.:
12/072629
Inventors:
Yang-Dar Yuan - Irvine CA, US
Scott M. Thacher - Costa Mesa CA, US
Elliott S. Klein - Danbury CT, US
Roshantha A. Chandraratna - Laguna Hills CA, US
International Classification:
A61K 31/382
A61K 31/196
A61K 31/352
A61P 3/06
US Classification:
514432, 514563, 514456
Abstract:
The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.